

Contact: Shirley Maltz, Room 9C26, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-3936.

Purpose: The committee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research training activities in the area of biological sciences related to mental health, with recommendations to the National Advisory Mental Council for final review.

Committee Name: Mental Health Small Grant Review Committee, NIMH.

Date and Time: March 5-6: 1:30 p.m.

Place: The Canterbury Hotel, 1733 N Street, NW., Washington, DC 20036.

Status of Meeting: Open—March 5: 1:30-3:30 p.m. Closed—Otherwise.

Contact: Betty Russell, Room 9C05, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-4843.

Purpose: The committee is charged with the initial review of applications for research in all disciplines pertaining to alcohol, drug abuse, and mental health for support of research in the areas of psychology, psychiatry, and the behavioral and biological sciences.

Committee Name: Epidemiology Subcommittee of the Epidemiologic and Services Research Review Committee, NIMH.

Date and Time: March 9-10: 9:00 a.m.

Place: Key Bridge Marriott, 1401 Lee Highway, Arlington, Virginia 22209.

Status of Meeting: Open—March 9: 9:00-10:00 a.m. Closed—Otherwise.

Contact: Gloria Yockelson, Room 9C14, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-1367.

Purpose: The committee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research and research training activities as they relate to mental health epidemiology, mental health service systems research, and evaluation of clinical mental health services, with recommendations to the National Advisory Mental Health Council for final review.

Substantive information may be obtained from the contact persons listed above. Summaries of the meetings and rosters of committee members may be obtained from Ms. Joanna Kieffer, Committee Management Officer, NIMH, Room 9-95, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-4333.

Dated: February 13, 1987.

Brenda L. Williamson,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 87-3566 Filed 2-19-87; 8:45 am]

BILLING CODE 4160-20-M

Centers for Disease Control

Aryl Amine Adducts in Blood as Indicators of Exposure; Open Meeting

The following meeting will be convened by the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control (CDC) and will be open to the public for observation and participation, limited only by the space available:

Date: March 19, 1987.

Time: 9 a.m. to 3 p.m.

Place: Auditorium, Robert A. Taft Laboratories, 4678 Columbia Parkway, Cincinnati, Ohio 45226.

Purpose: The purpose of this meeting is to review and discuss the utility of measuring blood hemoglobin or deoxyribonucleic acid (DNA) adducts as an indicator of aromatic amine exposure. Viewpoints and suggestions from industry, organized labor, academia, other government agencies, and the public are invited.

Additional information may be obtained from: Kenneth L. Cheever, Division of Biomedical and Behavioral Science, NIOSH, CDC, 4678 Columbia Parkway, Cincinnati, Ohio 45226, telephones: FTS: 684-8193, Commercial: 513/533-8193.

Dated: February 12, 1987.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 87-3560 Filed 2-19-87; 8:45 am]

BILLING CODE 4160-19-M

Center for Environmental Health; Open Meeting

ACTION: Notice of meeting.

The following meeting will be convened by the Center for Environmental Health (CEH), Centers for Disease Control (CDC), and will be open to the public for observation, limited only by the space available.

Time and Date: 9:00 a.m., Tuesday, March 10, 1987.

Place: Presidential Hotel, 4001 Presidential Parkway, Atlanta, Georgia 30340-3708.

Status: Open.

Matters To Be Considered: Discussion with leaders of communities in which lethal chemical warfare agents storage depots are located concerning the communities' ability to respond to an accidental agent release.

Contact Person for More Information: Ginny Jones, Program Specialist, CEH, CDC, 1600 Clifton Road, NE., Atlanta, GA 30333, Telephones: FTS: 236-4595, Commercial: 404/454-4595.

Dated: February 10, 1987.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 87-3559 Filed 2-19-87; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

Advisory Committee; Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meeting: The following advisory committee meeting is announced:

Dermatologic Drugs Advisory Committee

Date, time, and place. March 16, 8:30 a.m., Conference Rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 4:30 p.m.; Thomas E. Nightingale, Center for Drugs and Biologics (HFN-32), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4695.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in dermatologic disorders.

Agenda—Open public hearing. Interested persons who wish to present data, information, or views, orally or in writing, on issues pending before the committee should communicate with the committee contact person.

Open committee discussion. The committee will discuss the safety and efficacy of minoxidil (Upjohn) in male pattern baldness. The committee will also discuss requirements for proof of effectiveness of broad-spectrum sunscreens. The committee's discussions and conclusions regarding requirements for testing of UVA sunscreens may be

considered by the agency in its preparation of a tentative final monograph on over-the-counter (OTC) sunscreen drug products. Such a monograph is being developed as part of the OTC drug review. The advance notice of proposed rulemaking for these products was published in the *Federal Register* of August 25, 1978 (43 FR 38206).

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this *Federal Register* notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at

the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

A list of committee members and summary minutes of meetings may be requested from the Dockets Management Branch (HFA-305), Rm. 4-62, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: February 13, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87-3569 Filed 2-19-87; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 86F-0509]

U.S. Department of Agriculture, Food Safety and Inspection Service; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the U.S. Department of Agriculture (USDA), Food Safety and Inspection Service has filed a petition proposing that the food additive regulations be amended to provide for the safe use of sources of ionizing radiation for reduction of food-borne pathogens in poultry products.

FOR FURTHER INFORMATION CONTACT: Clyde A. Takeguchi, Center for Food Safety and Applied Nutrition (HFF-330), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7M3974) has been filed by USDA's Food Safety and Inspection Service, Washington, DC 20250, proposing that § 179.26 *Ionizing radiation for the treatment of food* (21 CFR 179.26) be amended to provide for the use of sources of ionizing radiation (gamma radiation, electron radiation, and X-radiation) to control food-borne pathogens by reducing the amount of microorganisms, such as *Salmonella*,

Yersinia, and *Campylobacter* in poultry products.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c).

Dated: February 9, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-3573 Filed 2-19-87; 8:45 am]

BILLING CODE 4160-01-M

National Institutes of Health

National Cancer Institute; Board of Scientific Counselors, Division of Cancer Etiology; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, Division of Cancer Etiology on March 5-6, 1987, Building 31, C Wing, Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892.

This meeting will be open to the public from 1 p.m. to recess on March 5 and from 9 a.m. to adjournment on March 6 for discussion and review of the Division budget and review of concepts for grants and contracts. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in section 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public from 9 a.m. to approximately 12 p.m. on March 5 for the review, discussion and evaluation of individual programs and projects conducted by the Division of Cancer Etiology. These programs, projects, and discussions could reveal personal information concerning individuals associated with the programs and projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winifred Lumsden, Committee Management Officer, National Cancer Institute, Building 31, Room 10A06, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members, upon request.

Dr. David McB. Howell, Executive Secretary of the Board of Scientific Counselors, Division of Cancer Etiology, National Cancer Institute, Building 31, Room 11A06, National Institutes of Health, Bethesda, Maryland 20892 (301/496-6927) will furnish substantive program information.

Dated: February 11, 1987.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 87-3602 Filed 2-19-87; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Cancer Clinical Investigations Review Committee; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Cancer Clinical Investigations Review Committee, National Cancer Institute, March 30-31, 1987, at the Omni Georgetown Hotel, 2121 P Street, Northwest, Washington, DC 20037.

This meeting will be open to the public on March 30 from 8 a.m. to 8:30 a.m. for reports by the Executive Secretary and Chairman of the Cancer Clinical Investigations Review Committee. Attendance by the public will be limited to space available.

In accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public on March 30 from approximately 8:30 a.m. until recess and on March 31 from 8 a.m. to adjournment for the review, discussion and evaluation of individual grant applications or cooperative agreements. These applications or cooperative agreements and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winifred Lumsden, the Committee Management Officer, National Cancer Institute, Building 31, Room 10A06, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members upon request.

Dr. Mary Ann Sestili, Executive Secretary, Cancer Clinical Investigation Review Committee, National Cancer Institute, Westwood Building, Room 836, National Institutes of Health, Bethesda, Maryland 20892, (301/496-7481) will provide substantive program information upon request.

Dated: February 11, 1987.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 87-3600 Filed 2-19-87; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Cancer Preclinical Program Project Review Committee; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Cancer Preclinical Program Project Review Committee, National Cancer Institute, April 2-3, 1987, National Institutes of Health, Building 31, Conference Room 9, Bethesda, Maryland 20892.

This meeting will be open to the public on April 2 from 8:30 a.m. to 9:15 a.m. to discuss administrative details. Attendance by the public will be limited to space available.

In accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public on April 2 from 9:15 a.m. to recess and on April 3 from approximately 9:15 a.m. to adjournment for the review, discussion and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winifred Lumsden, the Committee Management Officer, National Cancer Institute, Building 31, Room 10A06, National Institutes of Health, Bethesda Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members upon request.

Dr. Edwin M. Bartos, Executive Secretary, National Cancer Institute, 5333 Westbard Avenue, Room 826, Bethesda, Maryland 20892 (301/496-7565) will furnish substantive program information.

Dated: February 11, 1987.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 87-3601 Filed 2-19-87; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Cancer Therapeutics Program Project Review Committee; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the

Cancer Therapeutics Program Project Review Committee, National Cancer Institute, National Institutes of Health, April 16-17, 1987, Holiday Inn-Crowne Plaza, 1750 Rockville Pike, Bethesda, Maryland 20852.

This meeting will be open to the public on April 16 from 8 a.m. to 8:30 a.m., to discuss administrative details. Attendance by the public will be limited to space available.

In accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public on April 16 from 8:30 a.m. to 5 p.m. and on April 17 from 8 a.m. to adjournment for the review, discussion and evaluation of individual program project grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winifred Lumsden, Committee Management Officer, National Cancer Institute, Building 31, Room 10A06, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will furnish summaries of the meeting and roster of committee members upon request.

Dr. Suzanne E. Fisher, Executive Secretary, 5333 Westbard Avenue, Room 820, Bethesda, Maryland 20892 (301/496-2330) will provide other information pertaining to the meeting.

Dated: February 11, 1987.

Betty J. Beveridge,

Committee Management Officer, NIH.

[FR Doc. 87-3603 Filed 2-19-87; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; President's Cancer Panel; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the President's Cancer Panel, National Cancer Institute, March 16, 1987, at the UCLA School of Medicine, School of Nursing Auditorium, Louis Factor Building, A-660, Tiverton Drive, Los Angeles, California 90024.

This meeting will be open to the public on March 16 from 8:30 a.m. to adjournment. Agenda items include reports by the Chairman, President's Cancer Panel and the Director, National Cancer Institute; and reports and discussions from experts to obtain information regarding research